Loading company…
Texas-based biotech developing epigenetic cancer therapeutics, including Seclidemstat for Ewing sarcoma.
Founded in 2011 and based in Texas, US, Salarius Pharmaceuticals, Inc. develops therapeutics for pediatric and other cancers, including advanced solid tumors, using epigenetic enzymes. Its Seclidemstat is a reversible LSD1 inhibitor being developed for Ewing sarcoma. The company is at the seed stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in